Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Financial Perspectives Inc

Financial Perspectives Inc boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 119.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 459 shares of the medical research company’s stock after buying an additional 250 shares during the quarter. Financial Perspectives Inc’s holdings in Thermo Fisher Scientific were worth $239,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AMF Tjanstepension AB purchased a new stake in shares of Thermo Fisher Scientific during the third quarter worth approximately $42,409,000. Howard Capital Management Group LLC grew its holdings in Thermo Fisher Scientific by 0.5% during the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock worth $33,759,000 after acquiring an additional 286 shares during the period. Vest Financial LLC grew its holdings in Thermo Fisher Scientific by 205.1% during the third quarter. Vest Financial LLC now owns 1,620 shares of the medical research company’s stock worth $1,002,000 after acquiring an additional 1,089 shares during the period. Ledyard National Bank grew its holdings in Thermo Fisher Scientific by 4.4% during the third quarter. Ledyard National Bank now owns 3,165 shares of the medical research company’s stock worth $1,958,000 after acquiring an additional 132 shares during the period. Finally, Graybill Wealth Management LTD. grew its holdings in Thermo Fisher Scientific by 1.8% during the third quarter. Graybill Wealth Management LTD. now owns 12,506 shares of the medical research company’s stock worth $7,736,000 after acquiring an additional 223 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the transaction, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the transaction, the chief executive officer now owns 111,192 shares in the company, valued at $58,960,669.92. This trade represents a 8.25 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,125 shares of company stock valued at $11,231,699. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Bank of America lowered their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Bernstein Bank raised their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a report on Tuesday, October 22nd. Barclays cut their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Morgan Stanley raised their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Finally, Evercore ISI lowered their price objective on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $658.00.

Thermo Fisher Scientific Trading Down 1.7 %

Shares of NYSE TMO opened at $522.91 on Wednesday. The stock’s 50 day simple moving average is $548.15 and its 200 day simple moving average is $568.62. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company has a market cap of $200.01 billion, a price-to-earnings ratio of 31.63, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share repurchase program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.